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OBJECTIVES: In July 2000, Florida replaced a Federal law man-
dating all motorcycle riders to wear helmets with a state law
requiring helmets only for those <21 years, or with under $10,000
health insurance. Hospitalizations for motorcycle accident-
related injuries prior to and after the law changed were examined
to understand potential consequences. METHODS: Florida 
hospital databases for 13 quarters prior to January 4, 1997–
June 30, 2000) and after the change July 1, 2000–Septemebr 30,
2003), and published Florida motorcycle crash statistics were
examined. Hospitalized cases with crash-related injuries were
identiﬁed by via Emergency Department, ICD-9 diagnosis and E
codes (E810.2-E825.2, E810.3-E825.3). Injury type, demo-
graphics, costs, length of stay (LOS) and disposition were ana-
lyzed. Charges (accommodations and ancillary services) adjusted
by a 0.46 cost-to-charge ratio and appropriate inﬂation indices
are reported as costs (2005 US$). RESULTS: In the pre-repeal
period, 3914 inpatient motorcycle-related injury cases were iden-
tiﬁed (males: 86%; mean age: 35.6, mean LOS: 6 days); 6424
cases in post-repeal period (males: 87%, mean age: 36.4, mean
LOS: 6 days); due to a rise in reported motorcycle crashes (33%),
all related-injuries (44%) and deaths (66%) during 1997–2003;
however, broader E-code use may also be a factor. Among 
hospitalized cases, there were signiﬁcantly (p < 0.01) more head,
neck and cervical spinal cord injuries (45% vs 35%), and deaths
(2.9% vs. 2.2%) post-repeal. Although average LOS did 
not increase, average cost per day ($4093 vs. $3359), and 
per stay ($20,502 vs. $17,243) increased signiﬁcantly (p < 0.01)
post-repeal. Cumulative cost of inpatient care for motorcycle-
related injuries rose from $68 million to $132 million during this
period. CONCLUSIONS:Since universal helmet requirements
were relaxed, there has been a substantial increase in motorcycle
accident-related injuries overall, head injury hospitalizations, and
injury-related deaths. Beyond clinical and societal consequences,
these increases reﬂect an increased economic burden as well.
PAIN—Clinical Outcomes Studies
PPN1
OPIOID ASSOCIATED ERECTILE DISFUNCTION IN CHRONIC
PAIN PATIENTS
Marsh B1, Sampson JM
1North Florida /South Georgia VA Medical Center, Gainesville, FL,
USA
OBJECTIVES: To study the prevalence of erectile disorder in
males with chronic pain on opioids. Chronic pain can lead to
reduced quality of life and strain on relationships. Opioids them-
selves can lead to signiﬁcant side effects, including a reduction
in serum testosterone and interference in the hypothalamic—
pituitary-axis. METHODS: Male patients in an opioid clinic
with chronic pain on opioids were screened for erectile disorder.
RESULTS: Ninety ﬁve patients were screened and 27 patients
29%) were positive for the disorder. Only ten (37%) had
received treatment. CONCLUSIONS: Erectile disorder is an
under diagnosed and treated disorder in chronic pain patients on
opioids. Male patients with chronic pain should be routinely
screened for erectile disorders.
PAIN—Cost Studies
PPN2
IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY
LOSS,AND DIRECT HEALTH CARE COSTS USING THE
MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Parthan A, Shepherd MD, Lawson KA, Barner JC, Brown C,
Bohman T
University of Texas at Austin, Austin,TX, USA
OBJECTIVE: The objective of this study was to assess the impact
of back pain on absenteeism, productivity loss, and direct health
care costs using the Medical Expenditure Panel Survey (MEPS).
METHODS: Individuals between the ages of 18 and 65 years
who participated in the MEPS during 2000 were included in the
study. Back pain patients were identiﬁed using ICD-9 codes. The
predictors of absenteeism in individuals who experienced back
pain were identiﬁed using Zero-inﬂated negative binomial regres-
sion (ZINB). Absenteeism days due to back pain were estimated
based on the ZINB regression model. Productivity loss was esti-
mated using the human capital approach. RESULTS: In 2000,
the one-year period prevalence of back pain in individuals
between 18 and 65 years of age was 11.1%. About 16.3% of
the individuals who were employed and who reported back pain
experienced back pain due to work-related injuries. Ethnicity
and union contract were identiﬁed as signiﬁcant predictors of
likelihood of absenteeism in individuals who experienced back
pain. The signiﬁcant predictors of absenteeism rate were per-
ceived overall health status due to back pain, and ethnicity. The
mean number of absenteeism days due to back pain was esti-
mated to be six days and a total of nine million absenteeism days
were due to back pain. The total productivity loss due to back
pain-related absenteeism was estimated to be $3.6 billion and
the total direct health care costs was estimated to be $14 billion.
The average productivity loss due to back pain was estimated to
be $305 per person and the annual per-capita direct health care
cost due to back pain was $730. CONCLUSIONS: Back pain is
one of the most common and challenging problems in primary
care. The economic burden due to back pain is of concern to
employers, insurance agencies, policy decision makers and treat-
ment decision makers.
PAIN—Health Care Use & Policy
PPN3
THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS:
COST EFFECTS IN THE CALIFORNIA WORKERS’
COMPENSATION SYSTEM
Gitlin M1,Wilson L2
1University of California, San Francisco and Amgen, Inc, San Francisco,
CA, USA, 2University of California, San Francisco, San Francisco, CA,
USA
OBJECTIVE: The California Workers’ Compensation (WC)
drug pricing system effective in 2004 tied payments to the Medi-
Cal system, but 60% of National Drug Codes (NDC) in the WC
System lacked an equivalent Medi-Cal NDC; and many were
repackaged pharmaceuticals. A model of pharmaceutical distri-
bution and claims processing of repackaged pharmaceuticals was
deﬁned. We assessed the cost and utilization of repackaged phar-
maceuticals to determine potential lost savings to the California
WC system. METHODS: We used 2002 data from the Califor-
nia Workers’ Compensation Institute and Medi-Cal pharmacy
expenditures. We described the extent of lost savings due to
repackaged pharmaceuticals, compared the characteristics of
repackaged pharmaceuticals in the WC using ANOVA, and iden-
tiﬁed predictors of repackaged pharmaceuticals using GLM
regression. We also suggest alternative pricing systems for Medi-
Cal non-equivalent repackaged NDCs. RESULTS: Repackaged
pharmaceuticals represented 55% of the Medi-Cal non-
equivalent NDCs used, but only 21% of total WC costs
($8,494,297) were attributed to repackaged pharmaceuticals.
Approximately 88% of repackaged pharmaceutical costs were
for generic medications. Companies most commonly associated
with repackaged pharmaceutical costs were Southwood Phar-
maceuticals (33.1%) and Pharma Pac (31.7%). Overall, com-
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pared to the $125 million in savings attributed to the Medi-Cal
equivalent NDCs, an additional $8 million could be gained if
repackaged pharmaceuticals were priced with a relevant Medi-
Cal rate such as an average Estimated Acquisition Cost, an
overall savings of 35.8%. On a per prescription basis, the prac-
tice of repackaging costs an additional $20 when compared to a
Medi-Cal pharmacy dispensed reimbursement rate. CONCLU-
SION: This study informs new legislation being proposed to stop
the generous pricing of repackaged pharmaceuticals due to non-
equivalent NDCs. For the ﬁrst time we describe the practice of
repackaging pharmaceuticals and identify cost savings expected
with alternative pricing systems, but also identify the value of
repackaging pharmaceuticals for WC patients.
PPN4
PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO
PATIENT CONTROLLED ANALGESIA
Nuyts G, Jones MP
Johnson and Johnson, Raritan, NJ, USA
OBJECTIVES: Patient controlled analgesia (PCA) with pump
delivery is the mainstay of modern postoperative pain manage-
ment, with often better pain control compared to competing
methods. We performed a data mining study to identify the 
clinical and hospital infrastructure correlates of PCA use.
METHODS: Patients older than 18 years having major opera-
tive procedures expected to require strong opioid based post-
operative pain control were selected from the Premier Perspective
database. Obstetric patients were excluded. Two random
samples were selected: a training sample of N = 21,782 and a
validation sample of N = 21,538. Factor analysis mapped the 75
observed explanatory variables, not related to post-operative
pain method onto 17 independent factors. Patient segmentation
was performed based on cluster analysis. RESULTS: Thirteen
distinct clusters were identiﬁed each with distinguishing demo-
graphic, clinical, payor and hospital setting features. Percent of
PCA use in each of the segments ranged from 3% to 38%. Six
segments, accounting for 3.5%, 1.8%, 8.4%, 4.1%, 6.1% and
9.2% of the total population had PCA usage below 10%. Only
three segments had PCA usage more than 20% with 4.7%,
14.5% and 7.8% of the population. Qualitative evaluation indi-
cated that the primary factor determining whether a segment had
low or high PCA use was the circumstance of admission: for
urgent admissions PCA was lowest, while the highest PCA use
was observed in those segments characterized by elective admis-
sions. CONCLUSION: Use of PCA differs between segments in
a heterogeneous cohort of post-operative pain patients. That the
driver of this difference was admission source may suggest that
time required to prepare PCA is an important factor in its actual
use and that thus easier PCA methods may increase patient’s use
of PCA.
PAIN—Patient Reported Outcomes
PPN5
ADVANCES IN PAIN MEASUREMENT: ITEM RESPONSE
THEORY (IRT) BASED METHODS AND THE PAIN IMPACT
QUESTIONNAIRE (PIQ-6)
Becker J, Saris-Baglama RN, Bjorner JB, Kosinski M,Ware JE
QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To use IRT-based methods to develop a six-item
questionnaire (PIQ-6) measuring pain severity and pain impact.
IRT was used to: 1) identify the most informative items from a
bank of 65 items, 2) evaluate construct validity, 3) norm the PIQ-
6 to the US general population; 4) cross-calibrate it to the SF-
36v2 BP scale; 5) develop a simple scoring approach based on
response category weights matching the IRT score; and 6) build
a computerized version to facilitate monitoring and management
of pain. METHODS: Items analyses and selection were based on
data from two web-based general population samples (n = 782,
n = 829) and a chronic pain patients sample (n = 306). Norming
was achieved by recalibrating the IRT-based item parameter
using 1998 US representative norm data of the SF36v2 (n =
7069). Cross-calibration of the PIQ-6 and SF-36v2 was per-
formed by estimating the expected SF-36v2 BP scale score using
IRT-based item parameter. The PIQ-6 computerized version was
programmed with Microsoft Visual Basic. RESULTS: Six items
were identiﬁed that ﬁtted an unidimensional IRT model, showed
high measurement precision and did not show differential item
functioning. Construct validity was supported by high correla-
tions with other pain measures and strong discrimination of pain
patients and the general population. The PIQ-6 is normed so that
a score of 50 represents the US general population norm (sd =
10). A cross-calibration table of the PIQ-6/SF-36v2 was created
to facilitate communication between researchers using those 
different instruments. The simple hand scoring approach had 
satisfactory agreement with the IRT scores. The PIQ-6 was 
programmed as computerized stand-alone/PDA/online versions
allowing for an easy administration, scoring and immediate feed-
back reporting including interpretation guidelines. CONCLU-
SIONS: Pain measurement can be improved by using IRT and
computerized methods. Noteworthy advantages of the PIQ-6 are
the enhancement of measurement precision and coverage as well
as the facilitation of monitoring and managing pain.
PATIENT-REPORTED OUTCOMES
PRO1
RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL
COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE
DATABASE ANALYSIS
Kochevar JJ1,Williams TD1
1Kochevar Research Associates, Boston MA, USA
OBJECTIVES: Our objective was to examine results of different
calculation methods for compliance, persistence and medication
gaps using prescription reﬁll claims. METHODS: This was a ret-
rospective analysis of statin prescription claims in the Protocare
database from 1/1/96 to 12/31/02. Statistics were based on ﬁrst-
time statin users (no statin claims in last year) continuously
enrolled for a minimum of 2.5 years after their ﬁrst statin claim
(N = 45,754) and up to a maximum of 6 years. Compliance was
calculated as the “simple” medical possession ratio (MPR)—
days supply/ 365 days—and as “adjusted” MPR, systematically
accounting for gaps and surplus days supply. Persistence was cal-
culated as “continuous” statin persistence (no gap in supply
greater than 30 days) and as “any” statin supply per one year
periods. Gaps were calculated for number of gaps of one day or
more without days supply and average gap length in 365 days.
RESULTS: “Simple” MPR in the ﬁrst year of use was 62% (S.D.
= 0.36). For the same period “adjusted” MPR was 59% (S.D.
0.33) and lower for 50% of the sample. The average difference
was 0.04 (14.6 days). Approximately 34% of the sample was
continuously persistent thru year 1, falling to 21% in year 2;
however, 73 percent had at least one prescription in year 2. Com-
pliance, persistence and gaps varied year by year over patient’s
total coverage periods. CONCLUSIONS: Failure to account 
for gaps and cumulative surpluses in prescription reﬁlls can
distort compliance estimates. “Any” persistence statistics indi-
cate that a higher proportion of statin users remain intermittent
rather than discontinued over long periods of time. Statistics on
number and length of gaps are necessary to provide a full
